Automated drug design of kinase inhibitors to treat chronic myeloid leukemia

Medicinal Chemistry

ISSN: 2161-0444

Open Access

Automated drug design of kinase inhibitors to treat chronic myeloid leukemia

2nd International Conference on PHARMACEUTICAL CHEMISTRY

October 02-04, 2017 Barcelona, Spain

Aramice Y S Malkhasian and Brendan J Howlin

King Abdulaziz University, Saudi Arabia
University of Surrey, UK

Scientific Tracks Abstracts: Med Chem (Los Angeles)

Abstract :

Medicinal chemistry has in the past been dominated by learned insights from experienced organic chemists. However, with the advent of computer based methods, computer aided drug design has become prominent. We have compared here the ability of expert chemists to purely automated methods and found that the automated method produces a better potential candidate drug than the expert input. The example chosen is based on inhibitors to Abl-kinase and the successful anti-leukaemic drug imatinib. The proposed molecule is a simple modification of nilotinib which has a docking energy of 4.2 kJ/mol better than the best intuitive molecule.

Biography :

Aramice Y S Malkhasian completed PhD at Concordia University 1985. He was a Research Scientist at McGill. with M. A. Whitehead at 1995, at 2003 and 2004 work with Prof Michael Sevillaand Prof. Ferman Chaves at Oakland university. Currently professor at King Abdulaziz University

Google Scholar citation report
Citations: 6627

Medicinal Chemistry received 6627 citations as per Google Scholar report

Medicinal Chemistry peer review process verified at publons

Indexed In

arrow_upward arrow_upward